Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called NGM282 in people with a liver condition called Primary Sclerosing Cholangitis (PSC), which causes scarring of the bile ducts. A total of 62 people took part — 21 received a lower dose of NGM282 (1.0 mg), 21 received a higher dose (3.0 mg), and 20 received a placebo (a dummy treatment with no active ingredient). The trial mainly measured changes in a liver enzyme in the blood called alkaline phosphatase, which doctors often monitor in people with PSC. It also tracked several other liver-related substances in the blood. The reported data shows that for the main measure — the average change in alkaline phosphatase levels from the start of the trial — the 1.0 mg group saw an average increase of 25.6 units per litre, the 3.0 mg group saw an average decrease of 9.8 units per litre, and the placebo group saw an average decrease of 0.6 units per litre. In percentage terms, these changes were +7.1%, −4.2%, and −3.4% respectively. For two other liver enzymes (AST and ALT), the reported data shows the 3.0 mg group had larger average decreases compared to the 1.0 mg group and the placebo group, though the numbers varied across the two enzymes. For bilirubin (a substance that builds up when the liver is under stress), the 1.0 mg group showed a notable average increase, while the 3.0 mg and placebo groups showed only very small average changes. The rate-of-change data for alkaline phosphatase over time was only reported for the two NGM282 groups and was not reported for the placebo group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 33898959) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Primary Biliary Cholangitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a condition called Primary Sclerosing Cholangitis (PSC), which is a disease that causes scarring and narrowing of the bile ducts in the liver.
Who may not be able to join:
- You have a significant liver disease caused by something other than PSC.
- Your bile duct condition is caused by a different but similar disease, either "secondary sclerosing cholangitis" or a condition related to a protein called IgG4 (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.